All In Biotech

Drug Trial Radar · NCT05270460

Safety, PK and Efficacy of PCS12852 on Gastric Emptying Rate in Patients With Moderate to Severe Gastroparesis

A Phase 2A, Placebo-controlled, Randomized, Dose Response Study of the Safety, Pharmacokinetics and Efficacy of PCS12852 on Gastric Emptying Rate Assessed by 13C Spirulina GEBT in Patients With Moderate to Severe Gastroparesis

Last checked: Nov 20, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

25

Actual

Start

Mar 9, 2022

Primary completion

Sep 29, 2022

Study completion Oct 6, 2022

Sponsor

Lead sponsor
Processa PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Mar 8, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, placebo-controlled study that will compare the effect of 2 different dosage regimens of PCS12852 on gastric emptying time to placebo in both idiopathic gastroparesis (IG) and diabetic gastroparesis (DG) patients.

Conditions

  • Gastroparesis

Interventions

  • PCS12852Drug

    PCS12852 oral tablet administered once daily

  • PlaceboDrug

    Placebo comparator oral tablet administered once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Gastric Emptying Rate From Baseline as Determined by the Area Under the Curve (AUC) of the Gastric Emptying RateTime frame: ~28 days
  2. Change in Gastric Emptying Rate From BaselineTime frame: ~28 days
  3. Concentrations of PCS12852 in Plasma - CmaxTime frame: Day 1
  4. Concentrations of PCS12852 in Plasma - AUC0-lastTime frame: Day 1
  5. Concentrations of PCS12852 in Plasma - AUC0-lastTime frame: Day 28
  6. Concentrations of PCS12852 in Plasma - CmaxTime frame: Day 28

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • Torrance Clinical Research Institute, Inc.

    Lomita, California

  • TriWest Research Associates

    San Diego, California

  • APF Research, LLC

    Miami, Florida

  • International Research Associates, LLC

    Miami, Florida

  • University of Louisville

    Louisville, Kentucky

  • Delta Research Partners

    Bastrop, Louisiana

  • Long Island Gastrointestinal Research Group

    Great Neck, New York

  • M3 Wake Research

    Raleigh, North Carolina

  • Texas Tech University

    El Paso, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.